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Available online 2 December 2015Background: Contrast-induced acute kidney injury (CI-AKI) is associated with adverse outcomes. However, the
problem complicating CI-AKI relates to its deﬁnition.More than 30 deﬁnitions of AKI have been used in the liter-
ature. We examined the prevalence of CI-AKI according to three criteria. Prevalence of cardiovascular events ac-
cording to each criterion was also investigated.
Methods: We studied 247 consecutive patients with acute myocardial infarction (66.7 ± 9.0 years, 189 males)
who underwent primary percutaneous coronary intervention in our hospital. Three deﬁnitions of CI-AKI were
applied: (i) traditional CI-AKI, (ii) CI-AKI derived from RIFLE criteria, (iii) CI-AKI derived from AKIN criteria. Car-
diovascular events comprised in-hospital death, sudden death, cerebral infarction, heart failure, and acute coro-
nary syndrome.
Results: Prevalence of CI-AKI was 27.1% (67/247) according to the traditional CI-AKI deﬁnition, 23.9% (59/247)
according to the CI-AKI deﬁnition derived from RIFLE criteria, and 15.8% (39/247) according to the CI-AKI
deﬁnition derived fromAKIN criteria. Prevalence of cardiovascular events was 13.8% (34/247). Prevalence of car-
diovascular events with and without CI-AKI was 19.4% (13/67) and 11.7% (21/180) according to the traditional
CI-AKI deﬁnition (P = 0.13), 22.0% (13/59) and 11.2% (21/188) in the CI-AKI deﬁnition derived from RIFLE
criteria (P = 0.035), and 35.9%(14/39) and 9.6% (20/208) according to the CI-AKI derived from AKIN criteria
(P = 0.00001).
Conclusion: Prevalence of CI-AKI varies widely depending on the criteria used. The CI-AKI deﬁnition derived from
AKIN criteria was the most effective predictor of cardiovascular events.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acute myocardial infarction1. Introduction
Primary percutaneous coronary intervention (PCI) for patients with
acute myocardial infarction (AMI) enables rapid restoration of patency
of coronary arteries and contributes to salvage of the myocardium. Pri-
mary PCI also results in improvement of the prognosis.
In general, when employing coronary angiography (CAG) and CT an-
giography (CTA), injection of iodinated contrast media is undertaken,
but can result in contrast-induced acute kidney injury (CI-AKI). CI-AKI
is associated with in-hospital and long-term morbidity and mortality
[1–10]. Several risk factors for CI-AKI have been reported: advanced
age, acute myocardial infarction (AMI), chronic renal insufﬁciency, dia-
betes mellitus, congestive heart failure, depletion of intravascular vol-
ume, and a large volume of contrast media [5,11,12].a).
. This is an open access article underThemost widely used criteria of CI-AKI are an increase of serum cre-
atinine (sCr) ≥0.5 mg/dL or ≥25% above baseline values within 72 h of
an intervention. However, a consensus for AKI is lacking. More than 30
deﬁnitions of AKI have been used in the literature, creatingmuch confu-
sion and making inter-study comparisons difﬁcult [13–15]. A unifying
deﬁnition is very important and two attempts to deﬁne AKI have been
made. In 2004, the Acute Dialysis Quality Initiative (ADQI) Group, com-
prising experts in nephrology and critical caremedicine, published their
consensus deﬁnition for AKI: the Risk, Injury, Failure, Loss, and End-
stage kidney disease (RIFLE) classiﬁcation [16]. In 2007, the Acute
Kidney Injury Network (AKIN) Group, an international collaboration of
nephrologists and intensivists, proposed a modiﬁed version of the
RIFLE criteria: the AKIN criteria [17].
We wished to estimate the prevalence and prognosis of CI-AKI ac-
cording to these two CI-AKI deﬁnitions in patients with AMI who
underwent primary PCI. We also wished to evaluate which CI-AKI deﬁ-
nition was most effective for prediction of the long-term prognosis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline clinical and biochemical characteristics
Variable
Patients
(n = 247)
Age (years) 66.7±9.1
Male 77.0%
Risk factor for CAD
Diabetes mellitus 36.8%
Hypertension 66.8%
Dyslipidemia 64.4%
Smoking history 70.5%
Obesity (BMI N25 kg/m2) 36.4%
Family history of CAD 24.3%
Baseline laboratory data
Serum creatinine (mg/dL) 0.87±0.25
eGFR (mL/min/1.73 m2) 73.9±19.6
LDL-C (mg/dL) 128.4±30.6
HDL-C (mg/dL) 45.9±8.7
Triglyceride (mg/dL) 146.4±73.4
HbA1c (%) 6.4±1.0
Uric acid (mg/dL) 5.5±1.2
Hemoglobin (g/dL) 14.1±1.5
BMI: body mass index; eGFR: estimated glomerular ﬁltration rate; HDL-C,
high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-choles-
terol; CAD, coronary artery disease; HbA1c, glycated hemoglobin
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The study protocol was approved by the ethics committee of our in-
stitution. Written informed consent was obtained from all patients.
2.1. Study population
Between 1 July 2006, and 31 December 2011, we enrolled 274 con-
secutive patients admitted to our hospital with ST-elevation acutemyo-
cardial infarction (STEMI) treated with primary PCI within 12 h of
STEMI onset. The deﬁnition of STEMI was an increase in creatine kinase
(CK) level and creatine kinase MB (CK-MB) greater than 2 × 99th per-
centile of the upper limit together with evidence of MI-like symptoms
of ischemia, ST-elevation, and development of a pathologic Q wave
in the electrocardiogram. Exclusion criteria were end-stage renal
failure necessitating dialysis, an estimated glomerular ﬁltration rate
(GFR) b 30 mL/min/1.73 m2, death within 72 h, and PCI-related MI.
2.2. Study protocol
After primary PCI, patients received 0.9% sodium chloride (i.v.) for
≥12 h. The rate of infusion was 0.5–1.5 mL/kg/h according to left-
ventricular function. Initially, all patients received aspirin and
clopidogrel. Use of beta blockers, angiotensin-converting enzyme inhib-
itors, angiotensin II receptor blockers, support with diuretics or inotro-
pic drugs, or the indication of intra-aortic balloon pump (IABP) was
left to the discretion of the interventional cardiologist and Coronary
Care Unit (CCU) cardiologists. sCr was measured at the time of hospital
admission, just after PCI, at least every 24 h for the following 3 days, dis-
charge from the CCU and hospital, each outpatient visit, and upon re-
hospitalization. The eGFR was calculated using the Modiﬁcation of
Diet in Renal Disease study equation for Japanese subjects:
eGFR ¼ 194 agef g−0:287  sCrf g−1:094  0:734 if thepatient is femalef g
2.3. Primary PCI
Primary PCIwas carried out by a 24-h on-call interventional teamac-
cording to standard clinical practice. The recommended intervention
was coronary stenting. Heparin was injected via the intravenous
route. The activated clotting time (ACT) during PCI was 250–300 s.
The contrast media used for all patients was Iohexol 350.
2.4. Clinical deﬁnition
We used three deﬁnitions of CI-AKI in the present study. The ﬁrst
deﬁnition of CI-AKI was the most widely used, and was based on
absolute or percent increase in sCr after intervention procedures (the
“traditional” CI-AKI deﬁnition): an increase of sCr ≥0.5 mg/dL or ≥25%
above baseline values within 72 h.
The second deﬁnition of CI-AKI was derived from RIFLE criteria.
RIFLE criteria deﬁnes AKI as an increase in sCr ≥150% from baseline or
a decrease in the GFR ≥25% using sCr criteria, or b0.5 mL/kg/h for ≥6 h
using urine-output criteria. In the present study, CI-AKI derived from
RIFLE criteria was an increase in sCr ≥150% from baseline or a decrease
in the eGFR ≥25% within 72 h (CI-AKI derived from RIFLE deﬁnition).
The third deﬁnition of contrast-induced nephropathy (CIN) was de-
rived from AKIN criteria. AKIN criteria deﬁnes AKI as an increase in sCr
≥0.3 mg/dL or 1.5-times the baseline using sCr criteria, or b0.5 mL/kg/h
for ≥6 h using urine-output criteria, within 48 h. In the present study,
CI-AKI derived from AKIN criteria was an increase in sCr ≥0.3 mg/dL or
150% from baseline within 72 h (CI-AKI derived from AKIN deﬁnition).
In the present study, sCr upon hospital admission was used as base-
line sCr. We calculated the prevalence of CI-AKI using these threecriteria (traditional CI-AKI deﬁnition; CI-AKI derived from RIFLE; CI-
AKI derived from AKIN).
Cardiovascular events comprised in-hospital death, sudden death,
cerebral infarction, heart failure necessitating hospitalization, and
acute coronary syndrome (AMI and unstable angina pectoris).
The prevalence of cardiovascular events in patients with CI-AKI and
without CI-AKI using these three deﬁnitions was calculated. We
ascertained the most effective CI-AKI deﬁnition for the long-term
prognosis.
2.5. Statistical analyses
Continuous variables with a normal distribution were reported as
the mean ± SD. Categorical variables are presented as absolute values
and percentages. Comparison of continuous variables was undertaken
using the Student's t-test. Chi-square and Fisher exact tests were used
for comparison of categorical variables as appropriate. P b 0.05was con-
sidered signiﬁcant. Analyses were conducted using SPSS v11.0 (IBM,
Armonk, NY, USA).
3. Results
3.1. Clinical and procedural characteristics
Of the 274 consecutive patients with AMI who underwent primary
PCI from July 2006 to December 2011, 27 patients were excluded (3 pa-
tients had already received hemodialysis, 2 patients had undergone cor-
onary bypass surgery, 13 patients had died within 72 h, and 9 patients
did not return for follow-up visits). Hence, 247 patients (189 men and
58 women; mean age, 66.7 ± 9.1 years) formed the study cohort.
Baseline characteristics of patients and laboratory data of the entire
population are shown in Table 1. The baseline sCr was 0.87 ±
0.25 mg/dL and eGFR was 73.9 ± 19.5 mL/min/1.73 m2. Culprit lesions
were 52.2% (129/247) at the left anterior descending artery (LAD),
37.2% (92/247) at the right coronary artery (RCA), 9.7% (24/247) at
the left circumﬂex artery (LCX) and 0.8% (2/247) at the left main
trunk artery (LMT).
The volumeof contrastmedia aswell as infusion during PCI and after
PCI for 1 day was 152.1 ± 51.5 mL, 393.0 ± 190.4 mL, and 1495.8 ±
516.1 mL, respectively. Prevalence of use of an IABP or a distal protec-
tion device during PCI was 17.4% (43/247) and 6.9% (17/247), respec-
tively (Table 2).
Table 2
Procedural characteristics
Variable
Patients
(n = 247)
Artery containing the culprit lesion
Left anterior descending 52.2%
Left circumﬂex 9.7%
Right coronary 37.2%
Left main trunk 0.8%
Volume of contrast media (mL) 152.1±51.5
Volume of infusion during PCI (mL) 393.0±190.4
Volume of infusion after PCI for 1 day (mL) 1495.8±516.1
Use of intra-aortic balloon pump 17.4%
Use of distal protection device 6.9%
PCI, percutaneous coronary intervention
Table 4
Cardiovascular events
n = 34
In-hospital death 10
Sudden death 1
Heart failure 12
Cerebral infarction 3
Acute coronary syndrome
Acute myocardial infarction 4
Unstable angina pectoris 4
Table 5
Prevalence of contrast-induced nephropathy and the relationship with the long-term
prognosis
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the minimum eGFR after PCI was 62.0 ± 16.3 mL/min/1.73 m2. The
minimum level of hemoglobin (Hb) within 72 h after PCI was 11.4 ±
1.5 g/dL. Maximum levels of CK and CK-Mb were 2612 ± 121 IU/L and
249 ± 147 IU/L (Table 3).
3.2. Follow-up and prevalence of cardiovascular events
Mean follow-up was 2.6 ± 1.5 years. Prevalence of cardiovascular
events during follow-upwas 13.8% (34/247). Ten patients died in hospi-
tal and 1 patient died suddenly after discharge fromhospital. Twelve pa-
tients were admitted to hospital for heart failure and 3 patients were
hospitalized with cerebral infarction. Acute coronary syndrome oc-
curred in 8 patients (4 AMI and 4 unstable angina pectoris) (Table 4).
3.3. Prevalence of CI-AKI and relationship with the long-term prognosis
Prevalence of CI-AKIwas 27.1% (67/247) according to the traditional
CI-AKI deﬁnition, 23.9% (59/247) according to CI-AKI derived from
RIFLE, and 15.8% (39/247) according to CI-AKI derived from AKIN.
Prevalence of CI-AKI varied widely depending on the criteria used.
Prevalence of cardiovascular events with and without CI-AKI was
19.4% (13/67) and 11.7% (21/180) according to the traditional CI-AKI
deﬁnition (P = 0.13), 22.0% (13/59) and 11.2% (21/188) according to
CI-AKI derived from RIFLE (P = 0.035), and 35.9% (14/39) and 9.6%
(20/208) according to CI-AKI derived from AKIN (P = 0.00001)
(Table 5). The deﬁnition derived from AKIN was the most effective for
prediction of the long-term prognosis.
4. Discussion
Injection of contrastmedia can result in CI-AKI [10]. The exactmech-
anisms of CI-AKI have not been elucidated fully, but several causes have
been described. Increased adenosine-, endothelin-, and free radical-
induced vasoconstriction and reduced nitric oxide- and prostaglandin-
induced vasodilation have been observed. These mechanisms cause is-
chemia in the deep portion of the outer medulla, an area with high re-
quirements for oxygen, and remote from the vasa recta supplying the
renal medulla with blood. Contrast agents also have direct toxic effectsTable 3
Biochemical characteristics after primary PCI
Variable
Patients
(n=247)
Serum creatinine (mg/dL) 1.02±0.32
eGFR (mL/min/1.73 m2) 62.0±16.3
Maximum CK (IU/L) 2612±121
Maximum CK-Mb (IU/L) 249±147
Minimum hemoglobin (g/dL) 11.4±1.5
eGFR, estimated glomerular ﬁltration rate; CK, creatine kinase; CK-MB, crea-
tine kinase MB.on renal tubular cells, causing vasodilation, altered mitochondrial func-
tion, and apoptosis [6,16,18].
In general, CI-AKI is considered to be a reversible form of acute renal
failure. However, CI-AKI is of considerable concern because of its ad-
verse effects on outcomes, including prolonged hospitalization and in-
creased morbidity and mortality [2–5,11,19]. The risk of CI-AKI is
signiﬁcantly higher in patients with AMI because of hemodynamic in-
stability due to sudden left-ventricular dysfunction and use of a large
volume of contrast media. Therefore, there have been many reports fo-
cusing on short-term and long-term outcomes in patients with AMI un-
dergoing primary PCI. In these reports, a higher prevalence of prolonged
hospitalization, in-hospital mortality, and ≤3-year mortality in patients
with AMI has been demonstrated [1,7–9,20].
Efforts to reduce the occurrence of CI-AKI have garnered consider-
able attention in recent years. Several clinical trials focusing on preven-
tion of CI-AKI, including those using N-acetylcysteine, sodium
bicarbonate, and ascorbic acid, have been carried out in patients under-
going radiographic procedures with contrast media. However, there is
limited evidence that a pharmaceutical intervention can prevent CI-
AKI. Peri-procedural hydration with (preferably) intravenous adminis-
tration of 0.9% isotonic saline or an isotonic solution of sodiumbicarbon-
ate only can reduce the prevalence of CI-AKI [6,18,21,22].
However, the problem complicating CI-AKI relates to its deﬁnition.
Originally, CI-AKI was deﬁned as renal dysfunction caused by adminis-
tration of a contrast agent. More than 30 deﬁnitions of AKI have been
used in the literature, creating much confusion and making inter-
study comparisons difﬁcult. Two important parameters affect the deﬁ-
nition of CI-AKI: the increase in sCr after the procedure and the other
is the time after the procedure. Deﬁnitions of CI-AKI relating to an in-
crease in sCr listed in the literature are (i) N0.5 mg/dL, (ii) N25% and
(iii) N0.5 mg/dL or N25%. In one report, CI-AKI was deﬁned as a reduc-
tion in the eGFR b25%. The time after the procedure stated in the litera-
ture is (a) within 48 h, (b) within 72 h, (c) within 48 h or 72 h,
(d) within 4 days, (e) within 5 days and (f) within 7 days. These deﬁni-
tions vary greatly, so the deﬁnitions of CI-AKI used in the literature have
been mentioned in some reviews [13,14]. One study discussed the dif-
ference in the prevalence of CIN using different deﬁnitions of CIN:
(a) increase in sCr N0.5 mg/dL, and (b) increase in sCr N0.5 mg/dL orVariable
Patients
(n=247) P
Prevalence of CI-AKI
Traditional CI-AKI deﬁnition 27.1% (67/247)
CI-AKI deﬁnition derived from RIFLE 23.9% (59/247)
CI-AKI deﬁnition derived from AKIN 15.8% (39/247) 0.04
Prevalence of cardiovascular events
With CI-AKI by traditional deﬁnition of CI-AKI 19.4% (13/67)
Without CI-AKI by traditional deﬁnition of CI-AKI 11.7% (21/180) 0.13
With CI-AKI by CI-AKI derived from RIFLE 22.0% (13/59)
Without CI-AKI by CI-AKI derived from RIFLE 11.2% (21/188) 0.035
With CI-AKI by CI-AKI derived from AKIN 35.9% (14/39)
Without CI-AKI by CI-AKI derived from AKIN 9.6% (20/208) 0.00001
Table 6
Correlates of the long-term prognosis
OR
95% CI
Lower Upper P
CI-AKI by the traditional deﬁnition of CI-AKI 1.81 0.85 3.86 0.124
CI-AKI by CI-AKI deﬁnition derived by RIFLE 2.23 1.04 4.8 0.039
CI-AKI by CI-AKI deﬁnition derived by AKIN 5.24 2.35 11.66 b0.001
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in sCr N25% or 0.5 mg/dL within 72 h (the traditional deﬁnition in our
study). We used the CI-AKI deﬁnition derived from AKIN and RIFLE
and compared the prevalence of CI-AKI and long-term prognosis ac-
cording to these three deﬁnitions in patients undergoing primary PCI
with acute AMI. Prevalence of CI-AKI varied signiﬁcantly according to
the deﬁnition, andCI-AKI derived fromAKINwas themost effective pre-
dictor for the long-term prognosis in our report. In 2004, the ADQI
Group published their consensus deﬁnition for AKI: the RIFLE classiﬁca-
tion. RIFLE criteria was intended to establish the presence or absence of
the clinical syndrome of AKI in a given patient or situation, and to de-
scribe the severity of this syndrome [16]. In 2007, the AKIN group pro-
posed a modiﬁed version of the RIFLE criteria, and termed it the AKIN
criteria. The AKIN Group sought to increase the sensitivity of RIFLE
criteria by recommending that a small change in sCr be used as a thresh-
old to deﬁne AKI [17]. Recently, we became interested in CI-AKI because
CI-AKI is associated with mortality and morbidity [1–5,7,9,23,24].
Therefore, we investigated if mortality and morbidity is correlated
with CI-AKI according to each deﬁnition and the long-term prognosis.
The traditional CI-AKI deﬁnition was not signiﬁcantly associated
with the long-term prognosis. The CI-AKI deﬁnition derived from
AKIN and the CI-AKI deﬁnition derived from RIFLE were signiﬁcant pre-
dictors for the long-term prognosis, and the long-term prognosis was
most strongly associated with the CI-AKI deﬁnition derived from AKIN
(Table 6). AKIN criteria and RIFLE criteria were not designed to predict
mortality or adverse outcomes, but it is logical to assume that more se-
vere disease will result in a worse outcome. The AKIN Group also pro-
posed a time limit of 48 h for the diagnosis of AKI [17]. Therefore, we
examined the inﬂuence of time, and the results of prevalence of CI-AKI
and cardiovascular events with and without CI-AKI within 48 h after
the procedure are shown in Table 7. Within 48 h, the CI-AKI deﬁnition
derived from AKIN was also the most effective for predicting the long-
term prognosis. However, for the CI-AKI deﬁnition derived from AKIN
within 72 h of the procedure, the prevalence of cardiovascular events
with andwithout CI-AKIwere 35.9% (14/39) and 9.6% (20/208), respec-
tively, according to the CI-AKI deﬁnition derived from AKIN (P =
0.00001). Therefore, the CI-AKI deﬁnition within 72 h of the procedure
was more effective than the CI-AKI deﬁnition within 48 h of the proce-
dure for prediction of cardiovascular events.Table 7
Prevalence of CI-AKI within 48 h and the relationship with the long-term prognosis.
Variable (within 48h)
Patients
(n=247)
P
Prevalence of CI-AKI
Traditional deﬁnition of CI-AKI 21.9% (54/247)
Derived from RIFLE 17.8% (44/247)
Derived from AKIN 13.0% (32/247) 0.04
Prevalence of cardiovascular events
With CI-AKI by traditional deﬁnition of CI-AKI 18.5% (10/54)
Without CI-AKI by traditional deﬁnition of CI-AKI 12.4% (24/193) 0.25
With CI-AKI by CI-AKI deﬁnition derived from RIFLE 20.4% (9/44)
Without CI-AKI by CI-AKI deﬁnition derived from
RIFLE
172.3% (25/203) 0.16
With CI-AKI by CI-AKI deﬁnition derived from AKIN 34.4% (11/32)
Without CI-AKI by CI-AKI deﬁnition derived from
AKIN
10.7% (23/215) 0.0003The main limitation of our study was that we investigated a small
population that was admitted to a single center. Our ﬁndings should
be conﬁrmed in a large, multicenter clinical trial. Adults with chronic
kidney (CKD) disease carry an extraordinarily high risk for cardiovascu-
lar disease (CVD). The effect of race on getting renal impairmentwas re-
ported in the literature [25]. An excess CVD risk prevalence and
mortality existed in non-Hispanic black (NHB) with CKD versus non-
Hispanic white (NHW)with CKD. No statistical differencewas observed
in the other race groups including the Japanese versus NHW. Therefore
the deﬁnition of CKI may vary according to a race.
5. Conclusions
Prevalence of CI-AKI variedwidely depending on the deﬁnition used.
Prevalence of CI-AKIwas signiﬁcantly lowwhen using the CI-AKI deﬁni-
tion derived from AKIN. The CI-AKI deﬁnition derived from AKIN was
themost effective predictor of the long-term prognosis. Hence, the def-
inition derived from AKIN is the most suitable deﬁnition for CI-AKI.
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